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Type of
hypertension
Description Blood pressure range
Essential
hypertension
(major type)
Chronic elevation in
blood pressure with no
underlying disease
Both systolic and
diastolic blood
pressure are elevated
more than 140/
90 mmHg
Secondary
hypertension
(second
common type)
Chronic elevation in
blood pressure due to
underlying pathology
(mostly due to renal
problems)
Both systolic and
diastolic blood
pressure are elevated
more than 140/
90 mmHg
Malignant
hypertension
When blood pressure is
severely elevated and
causes an organ
damage
Both systolic and
diastolic blood
pressure are elevated
but the diagnosis made
mainly when the
diastolic blood
pressure is higher than
130 mmHg
Isolated
systolic
hypertension
Common in elderly
due to the loss of
elasticity of major
blood arteries
The systolic blood
pressure is higher than
140 mmHg while the
diastolic blood
pressure is close to the
normal range
Resistant
hypertension
When more than three
diﬀerent
antihypertensive
agents are prescribed
and blood pressure is
still elevated
Both systolic and
diastolic blood
pressure are elevated
more than
140/90 mmHg1. Introduction
Hypertension is a state of chronically elevated blood pressure
(BP) that leads to functional and structural changes of the
blood vessels. It is a very common disorder in man, affecting
about 25% of the general population (Schoen and Cotran,
1994). Hypertension is associated with an increased incidence
of coronary heart disease and cerebrovascular incidents.
The disease is currently believed to be multifactorial and there
is some evidence of familial inheritance which increases
susceptibility to the condition, however, it is also recognised
that lifestyle and environment are important factors in the
development of the disease. Ninety percent of hypertensive
patients suffer from essential hypertension in which there is
no known underlying cause (Ballinger et al., 2007). In the
remaining 10% of patients, hypertension is secondary to renal
disease or less frequent adrenal disorders (Schoen and Cotran,
1994). Table 1 shows the common types of hypertension with a
brief description for each type.
The kidney plays an important role in the control of BP by
way of the rennin–angiotensin system, sodium homoeostasis
and production of vasodepressor substances such as prosta-
glandins. Abnormalities in any of these systems can lead to
BP changes and they are all thought to play a role in essential
hypertension (Schoen and Cotran, 1994). Hypertension is
often accompanied by further complications such as impaired
renal function and structural changes to the vasculature
(Soergel and Schaefer, 2002). Whether renal dysfunction is as
a result of continued hypertension or the primary cause of
the hypertensive state is still under discussion. There is a view
that the changes in kidney function are a result of structural
and functional alterations caused by exposure of the kidney
to increased perfusion pressure (Cowley et al., 1995). It has
been shown that increased basal BP can exacerbate existing
structural changes in the kidney of the hypertensive patient
resulting in secondary hypertension (Rettig et al., 1990).
Hypertension can develop as a result of changes within the
brain or endocrine organs or alteration in the neural control
of salt and water excretion, which then increase BP thereby
affecting the kidney (Denton et al., 2006).
In patients with essential hypertension endothelium-
dependent relaxation is diminished (Linder et al., 1990;
Panza et al., 1990), and impaired endothelial vasodilation
can be improved by the antioxidant vitamin C, as shown by
forearm blood ﬂow measurements. This effect can be reversed
by the nitric oxide synthase (NOS) inhibitor (Taddei et al.,
1998).
In this review we considered the experimental animal as a
model of hypertension when both systolic and diastolic blood
pressure are elevated above the level of 140/90 mmHg.Furthermore, the animal model of hypertension that we
explored is considered as a model of essential hypertension.
2. Renal microvasculature
The kidney is divided into two major regions, the cortex and
the medulla and can be grossly divided into four zones: the
cortex, the outer stripe of the outer medulla, the inner stripe
of the outer medulla, and the inner medulla (Mattson, 2003;
Navar et al., 2008). The perfusion of these different regions
is highly heterogeneous. Total tissue blood ﬂow averages
700 ml min1/100 g1 of tissue in the renal cortex, is
300 ml/min1/100 g1 near the junction of the cortex and the
outer medulla, decreases to 200 ml min1/100 g1 in the inner
stripe of the outer medulla, and ranges from 50 to
Figure 1 Medullary microcirculation. Juxtamedullary glomeruli
originate at an acute angle from the interlobular artery. Most
blood ﬂow into the medulla arises from juxtamedullary efferent
arterioles. At the outer stripe of the outer medulla, juxtamedullary
efferent arterioles progress into descending vasa recta [DVR] and
form vascular bundles at the inner stripe of the outer medulla.
DVR around the exterior of the vascular bundles perfuse the
interbundle capillary plexus that supplies nephrons. DVR in the
centre of the bundles continue across the inner–outer medullary
junction to perfuse the inner medulla. The vascular bundles
disappear in the inner medulla with the vasa recta becoming
dispersed between thin loops of Henle, collecting ducts, and
ascending vasa recta [AVR]. AVR ascend to the cortex through
outer medullary vascular bundles. DVR have a continuous
endothelium (left inset) and are surrounded by contractile
pericytes. AVR are highly fenestrated vessels (right inset). Taken
from Navar et al. (2008), 550–683. Fig. 13.11, p. 567.
Hypertension and renal haemodynamics 443100 ml/min1/100 g1 in the inner medulla (Navar et al., 2008;
Pallone et al., 2012).
An adequate blood supply is crucial for the production of
an ultraﬁltrate from plasma and the ability to modify the ﬁl-
trate through reabsorption and secretion into the tubule
enables the kidneys to effectively carry out these functions.
The kidneys receive approximately 25% of total cardiac out-
put however the distribution is not uniform within the kidney.
The renal cortex receives approximately 90% of the total renal
blood ﬂow (RBF) and plays a major role in ultraﬁltration
within the kidney. A dense peritubular capillary plexus arising
from efferent arterioles within the cortex surrounds the proxi-
mal and distal convoluted tubules to facilitate the reabsorptionof the glomerular ﬁltrate (Navar et al., 2008; Pallone et al.,
2012). The remaining 10% of the RBF perfuses the medulla
through vessels arising from the postglomerular vasculature
(efferent arterioles) of the inner cortical or juxtamedullary
nephrons (Fig.1).
The efferent arterioles of the juxtamedullary nephrons enter
the outer stripe of the outer medulla and divide into a series of
vascular loops called vasa recta. The vasa recta descend into the
inner stripe of the outer medulla and form vascular bundles.
The descending vasa recta (DVR) in the centre of the bundles
continue into the inner medulla whereas the DVR on the outer
margins of the bundles give rise to a capillary plexus between
the vascular bundles in the outer medulla. The DVR found in
either the outer or inner medulla divide and eventually merge
to form ascending vasa recta (AVR) that carry metabolic sub-
stances that enter the medulla in the DVR blood back to the
cortex. To avoid the possibility of medullary hypoxia resulting
from this process the kidney has adapted to exert a subtle con-
trol over regional perfusion of the outer and inner medulla
(Mattson, 2003; Navar et al., 2008; Johns and Ahmeda, 2014).
3. Renal medullary blood ﬂow
Although the kidney strives to maintain its perfusion within
tight boundaries, considerable blood ﬂow ﬂuctuations do occur
under normal conditions. However should these ﬂuctuations be
prolonged, target organ damage can occur (Persson, 2002). The
renal medulla is renowned for its low rate of blood perfusion
(Cowley, 1997) and a minimal reserve of oxygen (less than
40%) (Heyman et al., 1997), therefore the maintenance of ade-
quate perfusion of this zone is critically important for its sur-
vival, for the functional integrity of the kidney and for the
appropriate renal regulation of body ﬂuid balance and arterial
pressure (Badzynska et al., 2003). The regulation of blood ﬂow
in the renal medulla has been a subject of interest for many
years. Previous reports by Persson (2002) indicate that the renal
medulla has control over its own blood ﬂow. It has also been
suggested that the renal medulla has an impaired autoregula-
tory capacity, or may even exhibit a complete passive blood
ﬂow response to renal perfusion pressure changes however
more recent ﬁndings have challenged this hypothesis
(Persson, 2002). The vascular architecture of the kidney
appears to be arranged in a way that protects the renal medulla
from ischaemic insults (Evans et al., 2004). The details of this
process are far from clear and much experimental evidence sug-
gests there may be a complex interaction between paracrine
agents and autocoids in modulating vasomotor tone at various
locations along the micro-vascular circuit (Pallone et al., 2012).
Given the importance of medullary perfusion in inﬂuencing
water and salt balance, it was necessary to determine which
location(s) along the micro-vascular circuit provides control
of medullary blood perfusion (MBP) (Pallone et al., 2012).
Pallone (1994) ﬁrst demonstrated that when DVR are isolated
from outer medullary vascular bundles in the rat kidney they
are capable of constricting at various foci after exposure to
contractile agonists such as Angiotensin II. Based on anatomic
considerations it is probable that DVR are an important site of
regulation. It has since been reported that this regulation is
mediated by contraction of the vasa recta pericytes (Pallone,
1994; Park et al., 1997; Pallone et al., 2012). The vasa recta
capillaries therefore appear to be capable of exerting regional
444 A.F. Ahmeda, M. Alzoghaibicontrol of blood perfusion to the renal medulla. Similar studies
using vascular casting methodology suggest that jux-
tamedullary glomerular arterioles are not the chief regulators
of MBP, which is consistent with the idea that outer medullary
descending vasa recta play a key role in MBP control (Evans
et al., 2004).
4. Kidney and blood pressure control
Guyton et al. (1972) reported that raised arterial pressure was
accompanied by increased urine ﬂow and sodium excretion by
way of the pressure-diuresis mechanism (Guyton et al., 1972).
By increasing urine ﬂow the effective circulating volume is
reduced and thereby normalises arterial BP. This process
enables the kidneys to control long-term arterial pressure by
monitoring blood volume. In genetic rat models of hyperten-
sion and using micropuncture techniques, Arendshorst and
Beierwaltes (1979) reported that higher BP than in the nor-
motensive model were necessary to excrete a given amount
of sodium (Arendshorst and Beierwaltes, 1979). Therefore,
hypertension can occur as a result of a malfunction of the
pressure-natriuresis system in the kidney, for example
impaired excretory ability of the kidney. This hypothesis is
supported by the fact that with anti-hypertensive treatment,
for example angiotensin converting enzyme (ACE) blockers,
there is an alteration in the pressure-natriuresis balance and
the return sodium and water excretion back to control levels
(Cowley et al., 1995).
The renal medulla speciﬁcally plays a crucial role in the
long-term control of arterial BP and water and salt
homoeostasis. Cowley et al. (1995) reported that the
pressure-natriuresis mechanism observed in the rat kidney
was related to renal blood ﬂow and BP in the vasa recta vessels
of the inner medulla. The medullary blood perfusion (MBP)
and its pressure natriuresis response is regulated by angioten-
sin II, prostaglandins and nitric oxide (Zou et al., 1998; Liu,
2009), amongst other paracrine and humoral mediators, which
are all known to play important roles in the control of renal
function. Factors which are known to reduce blood ﬂow in
the renal medulla such as sympathetic nerve activity, angioten-
sin II, Cyclooxygenase (COX) and nitric oxide synthase (NOS)
inhibition, are associated with increasing BP. Conversely fac-
tors related to increased medullary ﬂow such as prostaglandins
and angiotensin converting enzyme (ACE) inhibitors are
linked to reductions in BP. This supports the argument that
it is the renal medulla, speciﬁcally, which is important in the
regulation of BP and is therefore a vital region involved the
pathogenesis of hypertension (Cowley et al., 1995).
5. Animal models of hypertension
The kidney plays a crucial long-term role in the pathophysiol-
ogy of hypertension by way of structural changes and the
increased retention of ﬂuid and sodium. Animal models of
hypertension have been used to show the central importance
of the kidney in its pathogenesis. There are some important
similarities between animal models of hypertension and the
human condition. For example, there is a genetic component
of the disease that is believed to be polygenic (Ganten,
1987). There are a number of animal models of hypertension
that have been used in order to further our understanding ofthe condition. Tigerstedt & Bergman in 1898 developed the
concept of a relationship between kidney and BP when they
injected renin, extracted from kidneys, into the systemic circu-
lation and observed a sustained increase in BP (Tigerstedt and
Bergman, 1898). Another animal model of hypertension is the
rat renovascular model, otherwise known as the Goldblatt
one-kidney one-clip model (Goldblatt et al., 1934), this model
is characterised by a unilateral nephrectomy and an arterial
clip placed on the renal artery of the remaining kidney. Levy
et al. (2001) reported a mean arterial pressure (MAP) of
174 ± 11 mmHg 4 weeks after arterial clipping in the one-
kidney one-clip model (Levy et al., 2001). A similar one-
kidney one-clip model has been described by Wiesel et al. in
1997, in which MAP was reported to be 20 mmHg higher than
controls 4 weeks after surgery (Wiesel et al., 1997). Another
popular animal model of hypertension is the deoxycorticos-
terone acetate (DOCA)-salt hypertensive rat. This model is
reported to have increased Reactive Oxygen Species (ROS)
production and reduced angiotensin II activity (Beswick
et al., 2001).
Spontaneously hypertensive rats (SHR), a genetic hyperten-
sive rat model, develop consistently higher BP compared with
other strains, have increased activity of ﬂuid retention mecha-
nisms, sodium reabsorption and increased vascular resistance
(Grisk et al., 2002). It is possible to identify structural changes
in the genetically hypertensive rat kidney even before hyperten-
sion is apparent. The genetic model, SHR, is probably the
most comparable with the human form of the condition. The
preglomerular arterioles have a reduced lumen diameter and
increased maximal resistance by 14–36% compared to Wistar
rats (Skov et al., 1992).
Since the development of the ﬁrst animal models of hyper-
tension, major advances have been made in the development of
genetically hypertensive rats (Ganten, 1987). Okamoto et al.
(1974) produced a colony of rats by selectively inbreeding
Wistar rats with higher than normal BP and produced the
SHR colony (Okamoto et al., 1974). One hundred percent of
SHR develop hypertension and a MAP of 184 ± 17 at the
age of 10 weeks. The SHR develop complications associated
with hypertension similar to those occurring in human hyper-
tension, such as cerebral and myocardial lesions. Hypertension
in the SHR model develops as a result of increased peripheral
resistance, ﬁrst produced by neurogenic factors and later
structural vascular changes associated with increased vascular
protein synthesis (Okamoto et al., 1974). Enhanced vasocon-
strictor prostaglandin production in the SHR was reported
by Armstrong et al. in 1976 (Armstrong et al., 1976), where
they found elevated levels of Prostaglandin F2alpha
(PGF2a). A sub-strain of SHR has been developed, the
stroke-prone SHR (SHRSP) that is characterised by severe
hypertension, MAP above 230 mmHg, and 80% incidence of
stroke by 9–13 months of age (Okamoto et al., 1974). In a pre-
vious review about the animal models of hypertension, it was
suggested that the results are greatly inﬂuenced by the duration
of exposure to the causal factors, difference in animal species,
gender and the age of animals (Dornas and Silva, 2011).6. Stroke-prone SHR (SHRSP)
The SHRSP characteristically displays a more severe hyperten-
sion than the SHR. The SHRSP also demonstrates increase
Hypertension and renal haemodynamics 445vascular reactivity to vasoconstrictor substances such as angio-
tensin II and noradrenaline, in comparison to normotensive
Wistar rats (Berecek et al., 1980). The SHRSP have a higher
renovascular resistance than the Wistar, which is apparent
from an early age but becomes more pronounced after pro-
longed hypertension. An increased salt diet causes accelerated
development of hypertension in both the SHR and SHRSP,
however BP measurements have shown that SHRSP are more
salt-sensitive than SHR and that may cause greater renal dam-
age in SHRSP (Grifﬁn et al., 2001). Nagaoka et al. (1981)
reported that the SHRSP had autoregulatory control of renal
blood ﬂow (RBF) and glomerular ﬁltration rate (GFR), which
was operative over a higher BP range than that in Wistar rats
(Nagaoka et al., 1981). When perfusion pressure was reduced
so was the sodium and water excretion of the SHRSP, there-
fore it appears that SHRSP requires higher than normal BP
in order to efﬁciently excrete electrolytes and water. As well
as the increased severity of hypertension in the SHRSP in com-
parison to the SHR, Churchill et al. (2002) showed that the
SHRSP displayed other differences, namely increased intrinsic
susceptibility to renal damage (Churchill et al., 2002). They
proposed that there were genetic differences between SHR
and SHRSP that accounted for the increased incidence of
hypertensive lesions and malignant nephrosclerosis after only
4–6 weeks on a high-salt diet, the SHR showed little tubular
damage under similar conditions. The salt-induced kidney
damage was thought to be not only linked to the increase in
BP but also due to the vasculotoxic effects of salt (Grifﬁn
et al., 2001). In summary, the SHRSP have a higher BP level,
increased tendency for renal damage and nephrosclerosis and
are more salt-sensitive than SHR.
7. SHR and renal circulation
The SHR have characteristic differences in renal blood ﬂow
and renal function to the normotensive Wistar rat. These dif-
ferences are due in part to structural changes namely, vascular
remodelling caused by extracellular matrix deposition, hyper-
trophy and impaired vascular endothelium-dependent vasodi-
latation (Park et al., 2002). These factors cause a reduction
in lumen diameter and increased peripheral resistance and
therefore increased MAP. SHR display increased renal vascu-
lar resistance and increased reactivity to vasoactive substances
such as noradrenaline and angiotensin II (Berecek et al., 1980).
Stankevicius et al. (2002) showed that the arteries from hyper-
tensive animals, contracted with noradrenaline, have decreased
relaxation to acetylcholine (Stankevicius et al., 2002). This
effect was proposed to be due to exposure of the arteries to
the increased intraluminal pressure, because the extraluminal
endothelium was found to be normal. The SHR have higher
haematocrit levels and display increased platelet aggregation
when exposed to thrombotic stimuli in comparison to nor-
motensive Wistar rats (Lominadze et al., 1997).
Cowley et al. (1995) showed that in SHR compared to nor-
motensive Wistar controls, renal MBP and sodium excretion
were lower while cortical ﬂow was similar (Cowley et al.,
1995). These measurements were carried out using a laser
Doppler ﬂowmeter and indicated that MBP in SHR was
reduced even before the appearance of hypertension. This
apparent lower blood ﬂow was accompanied by a raised vascu-
lar tone in the afferent arterioles of the juxtamedullarynephrons. With prolonged hypertension the cortex was also
reported to become involved in the development of glomerular
lesions and renal disease. In summary, the SHR have charac-
teristic differences in renal blood ﬂow and renal function to
the normotensive Wistar rat. SHR display increased renal vas-
cular resistance and increased reactivity to vasoactive sub-
stances. Also in SHR renal MBP is lower than that observed
in normotensive control rats.
8. SHR and the renin–angiotensin system (RAS)
After over a century of studies the RAS is now recognised as
an endocrine, paracrine and intracrine system which plays
important roles in aldosterone synthesis, blood pressure con-
trol and body ﬂuid balance (Zhuo and Li, 2011; Achard
et al., 2001).The renin angiotensin system is a network of hor-
monal cascades which regulates cardiovascular, adrenal and
renal function predominantly through the use of the angioten-
sin hormones. This system has been the target for many drugs
in order to combat hypertension and other cardiovascular
related events (Nguyen Dinh Cat and Touyz, 2011).
RAS can be described as a dual function system which bal-
ances between the vasoconstrictor, proliferative actions of Ang
II and the vasodilator, anti-proliferative function of Ang-(1–7)
(Pinheiro, 2012).
Components of the RAS have been implicated in contribut-
ing to the development of hypertension and increased expres-
sions of some of the constituents of the system have been
found in the SHR (Obata et al., 2000). With regard to the
endothelial dysfunction observed in hypertension, angiotensin
II-stimulated NADH/NADPH oxidase activity and subse-
quent superoxide anion production appears to mediate the
development of hypertension. Indeed, in rats made hyperten-
sive by infusions of angiotensin II, endothelium-dependent
vascular relaxations are impaired. The vessels show an
increased NADH/NADPH oxidase activity and produce
increased amounts of superoxide anions (Rajagopalan et al.,
1996).
Two types of Ang II receptors were pharmacologically
described in 1993 and classiﬁed as the AT1 and AT2 receptors
(Meister et al., 1993; Miyata et al., 1999). To date the AT1
receptor has been shown to mediate most of the physiological
actions of Ang II (Sadoshima, 1998) and was localised to the
outer medullary proximal tubules using in situ hybridisation
in rat kidneys by (Meister et al., 1993). Zhuo et al., 1992 also
reported high levels of AT1 receptor binding in glomerular
mesangial cells and in renal interstitial cells located between
the tubules and vasa recta bundles within in the inner stripe
of the outer medulla of rats (Zhuo et al., 1992). Ang II directly
constricts vascular smooth muscle cells and it is this vasocon-
strictor effect that contributes to the regulation of renal func-
tion and BP (Rajagopalan et al., 1996). Ang II plays a very
important role to increase the intra-glomerular pressure by
constricting the efferent arterioles at the glomerulus.
Angiotensin II stimulates NADPH oxidase and therefore
the production of oxygen radicals via AT1 receptors in the jux-
taglomerular apparatus, diminishing NO signalling in the SHR
by shortening its half-life (Schnackenberg, 2002). Inhibition of
angiotensin II activity by way of AT1 receptor blockade,
reduces ROS mediated NO inactivation (Vaziri et al., 2002).
However, there is excessive vasoconstriction in the renal
446 A.F. Ahmeda, M. Alzoghaibivessels of the SHR that cannot be solely attributed to angio-
tensin II action on the AT1 receptors (Welch and Wilcox,
2001). ACE inhibitors are an effective therapy for hyperten-
sion as they lower BP and have further beneﬁcial effects on
both systemic vasculature and the kidney (Grifﬁn et al.,
2003). Harrap et al. (1990) showed that the treatment of young
SHR with the ACE inhibitor perindopril resulted in a marked
reduction in MAP. They reported that after the withdrawal of
the treatment MAP increased but plateaued at a reduced level
in comparison to normal SHR. They also proposed that per-
manent structural changes occurred within the kidney causing
the reduction of MAP to persist even when ACE inhibitor was
stopped (Harrap et al., 1990).
It was postulated by Brenner et al. (1988) that increased BP
in the SHRSP was caused by a decreased ﬁltration surface area
in the glomerulus or a reduced number of nephrons causing
sodium retention and the resulting rise in the BP (Brenner
et al., 1988). Hypertension, therefore, could exacerbate the sit-
uation by causing further damage to the existing glomeruli.
Iversen et al. (1998a,b) reported that increased glomerular cap-
illary pressure in the SHR resulted in increased glomeruloscle-
rosis (Iversen et al., 1998a). It is thought that ACE inhibitors
stimulate glomerular growth and so may account for its per-
manent beneﬁcial effect on hypertension. In contrast, Black
et al. (2001) showed that ACE inhibitors had no effect on
the glomerular number or size in the SHR which were lower
than in the Wistar (Black et al., 2001). In summary, angioten-
sin II stimulates NADPH oxidase activity, produces increased
amounts of oxygen radicals (superoxide) and diminishes NO
signalling in the SHR. Treatment of SHR with ACE inhibitor
decreases blood pressure, and so it can be concluded that the
renin–angiotensin system plays an important role in maintain-
ing the high BP levels in the SHR.9. SHR and autoregulation of blood ﬂow
Iversen et al. (1998a,b) had previously shown that despite
increased cortical perfusion pressure in the SHR, their ability
to autoregulate the RBF and GFR was unaltered (Iversen
et al., 1998b). The autoregulatory system adapts to the
increased BP of the SHR, which develops with age, and the
pressure limits around which the autoregulation mechanism
works are reset to a higher level. If the MAP level of the
SHR is reduced the autoregulatory mechanism compensates
and resets to a lower pressure. This phenomenon of resetting
could be as a result of interaction with the renal nerves or
changes in plasma renin levels (Iversen et al., 1998b).
Tubuloglomerular feedback (TGF) is effective in both nor-
motensive and hypertensive rat strains and there is little differ-
ence in feedback response kinetics between strains, indicating
that TGF does not play a role in the pathogenesis of hyperten-
sion (Daniels and Arendshorst, 1990). Ren et al. (2002) sug-
gested that intracellular superoxide in the macula densa
enhanced TGF (Ren et al., 2002). This is due to superoxide
scavenging NO, which effectively decreases its availability.
Thus, superoxide may exert an enhanced inﬂuence on TGF
under normal conditions. It may also act as an important fac-
tor under pathological conditions associated with high levels of
superoxide and impaired endothelial function.
Renal prostaglandins are necessary for the normal func-
tioning of the kidney, as indicated previously. There isevidence that there is increased prostaglandin synthesis in the
kidney of the SHR, which becomes more severe with age
(Schirner and Taube, 1993). Iversen et al. (1992) showed that
prostaglandins are necessary for RBF autoregulation in the
SHR and their effect was dependent on the renal nerves. In
the same study, it was found that the inhibition of prostaglan-
din production by a cyclooxygenase inhibitor indomethacin
attenuated RBF autoregulation in the SHR, provided that
the kidney was innervated (Iversen et al., 1992). Renal tissue
damage such as that caused by genetic hypertension in rats is
generally not evenly distributed. There is evidence of glomeru-
losclerosis and tubular atrophy in the juxtamedullary cortex of
the SHR at a time when there is much less in the superﬁcial
cortex (Roald et al., 2002).
10. SHR and reactive oxygen species
Oxidative stress in the vasculature has been implicated in the
development of increased BP of the SHR. It has been argued
that increased ROS production in the kidney is important in
renal dysfunction associated with hypertension. ROS can
affect the vascular endothelium of the kidney by way of reduc-
ing NO availability, or by oxidising arachidonic acid resulting
in the generation of vasoactive products. ROS are present in
low concentrations in all cell types and their levels are strictly
regulated by constitutive scavenging systems, for example,
superoxide dismutase enzyme (SOD) (Makino et al., 2002).
Increased levels of ROS in the kidney of SHR have been impli-
cated in the pathogenesis of hypertension. Acute and long term
studies indicate that increased production of ROS play a part
in the development of increased renal vascular resistance and
increased sensitivity of TGF and therefore increased MAP in
the SHRSP model. It has been demonstrated that intravenous
infusion of SOD can lower BP in hypertensive rats (Nakazono
et al., 1991).
Studies in which SOD-like compounds, such as Tempol or
Vitamin C, were administrated in vivo resulted in a reduction
in BP and increased the diameter of renal blood vessels
(Makino et al., 2002; de Richelieu et al., 2005). Makino
et al. (2002) also demonstrated that in the normotensive
Sprague–Dawley rats, acute intramedullary infusion of
DETC, a SOD inhibitor, resulted in increased medullary
superoxide anion concentrations, reduced renal blood ﬂow
and a sustained increase in BP. Intravenous infusion of
DETC resulted in no change in BP, which suggested that the
increased oxidative stress in the renal medulla was solely
responsible for the observed increase in BP (Ahmeda and
Johns, 2012). The role of superoxide anions in the progression
of hypertension is further supported by work carried out by
Park et al. (2002) in which Tempol, a SOD mimetic, was
infused into the renal medulla of SHRSP, resulting in
decreased levels of ROS and attenuation of the progression
of hypertension (Park et al., 2002).
11. SHR and nitric oxide
Impaired release of NO occurs in most animal and human
models of hypertension, contributing to the increased periph-
eral resistance and most likely to the development of cardio-
vascular complications. Many in vitro studies have reported
endothelial dysfunction in thoracic aortae of SHR (Konishi
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1987; Shirasaki et al., 1988). Nitrite and Nitrate levels in the
SHR however are increased due to enhanced expression of
constitutive NOS, despite impaired endothelium-dependent
relaxation in the kidney of SHRSP (Stankevicius et al.,
2002). NO seems to play a smaller role in tubular and vascular
regulation than in the Wistar rats, which may contribute to the
SHR having an impaired pressure natriuretic response and
increased vascular resistance.
There is a high concentration of constitutive NOS
(endothelial NOS (eNOS) and neuronal NOS (nNOS)) present
in the endothelium of the renal tubules of SHRSP that is per-
haps due to a compensatory up regulation of expression.
Increased ROS may cause an increase in NOS enzyme produc-
tion, particularly inducible NOS (iNOS), in order to counter-
act the negative effects of ROS on renal haemodynamics
(Vaziri et al., 2002).
Hypertension has often been linked to changes in blood
vessel properties. There is increased whole blood viscosity
due to increased plasma protein concentrations including ﬁb-
rinogen in the SHR. There is also evidence that endothelial cell
alteration and changes in platelet activity in hypertension are
crucial in the development of thrombotic lesions. Lominadze
et al. (1997) reported that the SHR displayed increased platelet
activation in the presence of thrombotic stimuli and an
increased haematocrit compared to Wistar rats, which con-
tribute to the hypertensive state of the SHR (Lominadze
et al., 1997). This was supported by data presented by
Yamashita et al. (2002), who found that platelet activation
of SHRSP was decreased in vitro but also showed thrombus
formation was increased in vivo (Yamashita et al., 2002).
NO generation by the vascular endothelium causes vasodilata-
tion and prevents platelet aggregation in the rat. It was shown
that the vascular endothelium of the SHRSP had impaired NO
generation compared with the Wistar, which could have
occurred as a result of vascular damage due to increases in
BP and could account for its increased thrombus formation
(Yamashita et al., 2002). Vaziri et al. (1998) have published
data in which they reported that there is an increase in NO
production and eNOS and iNOS protein concentration in the
young SHR in comparison to the Wistar (Vaziri et al., 2002).
Ichihara et al. (2001) reported that despite normal NOS
activity NO, actions in the renal vasculature of the SHR are
impaired, and this phenomenon was contributed to by the
presence of oxygen radicals (Ichihara et al., 2001). NOS activ-
ity in the renal vessels of SHR has been shown to be equal to
that in normotensive Wistar rats and NO is produced by the
endothelium of SHR and Wistar rats in equal amounts.
However, the vascular relaxing action of NO was diminished.
Superoxide ions scavenge NO to form peroxynitrate, which is
a less potent vasodilator than NO and has a shorter half-life
(Ichihara et al., 2001). It has been shown by Grunfeld et al.
(1995) that the increased production of superoxide radicals
in the SHR is responsible for scavenging endothelial NO and
thereby causing increased vascular resistance and the charac-
teristic increase in BP (Grunfeld et al., 1995). However in
another study they found that in vitro superoxide scavengers
or increased NOS substrate failed to restore NO release from
endothelial cells of the SHR to levels similar to those of the
Wistar endothelium (Stankevicius et al., 2002). The evidence
suggested a link between the impaired renal activity of
NO on the vascular endothelium and the characteristichypertension of the SHR. In relation to L-arginine pathway
whether that normal or enhanced in the SHR and SHRSP a
recent study suggested that the renal medullary uptake of
L-arginine is impaired in SHR which mechanistically explaining
reduced NO production (Rajapakse et al., 2012).
Cowley et al. (1995) showed that in the SHR renal MBP
was lower in comparison to Wistar rats, but cortical ﬂows were
the same. These authors used laser-Doppler ﬂowmetry to mea-
sure renal blood ﬂow, and they indicated that MBP in the SHR
was reduced in comparison to the Wistar rat even before the
appearance of hypertension. This apparent reduction in
MBP was accompanied by increased vascular tone in the affer-
ent arterioles of juxtaglomerular nephrons (Cowley et al.,
1995). With prolonged hypertension the cortex can also
become involved with the development of glomerular lesions
and renal vascular degeneration.
Vascular differences between the SHRSP and the Wistar
rat, such as increased vascular resistance, may be due to the
alteration in reactive oxygen species and NO availability. It
has been reported that in a rat model of hypertension
(SHR), the concentration of superoxide anion is at a high level
in the renal medulla compared to the normotensive rats.
Indeed, Kerr et al., 1999 conﬁrmed that NO production was
greater in SHR compared with normotensive rats. In relation
to the SHRSP, it could be argued that superoxide anion pro-
duction overrides the enhanced NO generation and counter-
acts its action (Kerr et al., 1999).
In summary, it has been shown that the increased produc-
tion of superoxide radicals in the SHR is responsible for scav-
enging endothelial NO and thereby causing increased vascular
resistance and the characteristic increase in BP. The evidence
suggests a link between the impaired renal activity of NO on
the vascular endothelium and the characteristic hypertension
of the SHR.
12. Hypertension and NOS
Genetic manipulation to the gene that codes for eNOS in mice
has been shown to lead to the development of hypertension
(Huang et al., 1995). Therefore impaired NO mediated vasodi-
latation is believed to contribute to the hypertensive state. NO
plays a major role in reducing the systemic vascular resistance.
It is therefore considered that endothelial vasodilator dysfunc-
tion could precipitate hypertension. Indeed, an endothelial
abnormality is associated with hypertension in animal models
(Luscher et al., 1987). Depending on the experimental model,
the reduction in endothelium-dependent relaxation is due to
attenuation of endothelium mediated NO-dependent activity
or it is due to the augmented elaboration of an endothelium-
derived contracting factor (possibly a prostanoid). Whether
endothelial dysfunction is primary in the initiation of hyper-
tension or merely an epiphenomenon is not clear. Treatment
of the elevated BP normalises endothelium-dependent relax-
ation suggesting that the endothelial abnormality is secondary
in the hypertensive process (Cooke and Dzau, 1997a,b;
Luscher et al., 1987; Shultz and Raij, 1989). Conversely, infu-
sion of NOS antagonists produces a marked increase in BP in
experimental animals (Ribeiro et al., 1992). These inhibitors
have been considered non-speciﬁc, and the effect on BP could
conceivably be due to an effect on nNOS. However, more
deﬁnitive data for a primary role of NO in the regulation of
BP was provided by Huang et al. in 1995 (Huang et al.,
448 A.F. Ahmeda, M. Alzoghaibi1995). They found that inactivation of the mouse endothelial
NOS gene by homologous recombination produced mice that
were signiﬁcantly hypertensive.
There is extensive evidence for endothelial vasodilator dys-
function in hypertensive humans (Linder et al., 1990; Panza
et al., 1990). The most direct evidence has come from measure-
ments of forearm blood ﬂow by strain-gauge plethysmography
in response to intra-arterial infusions of endothelium-
dependent and independent vasodilators. In young patients
with mild essential hypertension, endothelium-independent
vasodilation is relatively undisturbed. In contrast, cholinergic
vasodilation (presumably endothelium-dependent) is attenu-
ated. Whether this is a primary or secondary phenomenon is
not known. The impairment of endothelium-dependent
vasodilation is likely multifactorial and may involve abnormal-
ities of signal transduction, NO activity, or NO biosynthesis.
There is preliminary evidence that, at least in some cases, the
endothelial deﬁcit may precede the appearance of essential
hypertension (Panza et al., 1990). In young normotensive indi-
viduals with hypertensive parents cholinergic forearm vasodi-
lation is impaired; in contrast, endothelium-independent
vasodilation is normal (Cooke and Dzau, 1997b).
13. SHR and endothelin-1 (ET-1)
Endothelins are a paracrine regulator, and are a family of 21-
amino acid peptides produced by endothelial cells which act at
vascular smooth muscle to produce vasoconstriction. Three
pharmacologically distinct iso-peptides of endothelin arising
from three different genes have been identiﬁed in mammalian
species; in humans, endothelin-1 appears to be functionally
the most important in both health and disease (Yanagisawa
et al., 1988; Inoue et al., 1989).
Two main endothelin receptors have been identiﬁed in
humans. The ETA receptor is present on vascular smooth mus-
cle cells, and stimulation of this receptor leads to a vasocon-
strictor response. In contrast, activation of the endothelial
ETB receptor results in vasodilatation through NO release.
The ET-1 stimulated the release of nitric oxide, which modu-
late the ETA receptor-mediated contraction of the vascular
smooth muscle. When ET-1 is administered intravenously,
there is a transient hypotensive (vasodilator) response followed
by a prolonged hypertensive (vasoconstrictor) response. The
initial vasodilation is due to NO release, whereas the pro-
longed vasoconstrictor response is due to ET-1 acting on
smooth muscle ETA and ETB receptors. NO also inhibits the
formation of ET-1. Therefore, there are complex interactions
between NO and ET-1 actions on blood vessels. A third
Endothelin receptor has been identiﬁed in Xenopus laevis
and shown to have a high afﬁnity for endothelin-3; however,
the human homologue of this receptor has yet to be identiﬁed
(Schwerte et al., 2002).
Activation of the ETA receptor by endothelin-1 stimulates
the release of arachidonic acid via the activation of cytosolic
phospholipase A2 (Trevisi et al., 2002). This may in turn result
in the synthesis of other endothelium-dependent vasoactive
factors such as PGI2 and thromboxane A2. Additionally,
endothelin-1 has been reported to promote COX-2 expression
as well as prostaglandin synthesis in vitro. Thus, besides acting
as a potent vasoconstrictor in its own right, endothelin-1 also
may promote release of other endothelium-dependent con-
tracting factors (Molnar and Hertelendy, 1995).Activation of endothelin system is a characteristic for SHR
and that the SHR have an endothelin-dependent component
(Shariﬁ et al., 1998; Schiffrin, 1999).
Infusion of ET-1 into renal artery exerts an effect on renal
microvasculature which leads to vasoconstriction. That effect
conﬁrmed to be through the ETA and ETB receptors which
found in the renal blood vessels. Interestingly when ETA recep-
tor blocked, the vasoconstriction response remains the same
due to the fact that the ET-1 exerts the vasoconstrictor action
on ETB receptor (Gellai et al., 1994; Just et al., 2004; Matsuura
et al., 1996; Wellings et al., 1994).
In previous studies that investigated the role of ET-1 in the
SHR model and the overall results of those studies were not
similar. The endothelin system does not seem to play a vital
role in SHR. (Lariviere et al., 1993,1995; Schiffrin et al.,
1995; Li and Schiffrin, 1995). However, some studies have con-
ﬁrmed that increased vasoconstrictor responses to ET-1
(Miyauchi et al., 1989; Cargnelli et al., 1990) and that the role
of endothelin is exist in SHR.
Other reports supported the later ﬁndings and provided fur-
ther evidence for the important role of Endothelin in regulat-
ing the renal function in SHR, after administration of ET-1
antagonist the renal function correspondingly improved
(Kato et al., 1995; Bird et al., 1995).
In a different study where the effect of intrarenal adminis-
tration of Endothelin receptors blockade, in both SHR and
Wistar rats, was investigated and the result showed no changes
on renal hemodynamic or excretory function in Wistar rats.
However, Endothelin receptors blocker within the kidney
improves renal hemodynamic and excretory function in the
SHR (Kato et al., 1995).
14. Conclusion
This review article provided a summary for the factors that
inﬂuencing the renal hemodynamic in SHR and explored
brieﬂy the mechanisms by which those factors can affect the
renal circulation.
In conclusion, it is apparent that the development of hyper-
tension in SHR is a result of complex mechanisms which
involve many factors and molecules that may act directly on
the renal blood vessels or interacting with other autocrine
and paracrine factors, whether locally or systematically, that
resulted in a modiﬁcation of the tone of the renal blood vessels
hence affect the renal function and blood pressure.
Hopefully this review will provide the basis for the subse-
quent articles to explore the other factors that may contribute
in the development of hypertension due to their local effect on
renal circulation.
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